면책 고지: 이 사이트는 FDA, ClinicalTrials.gov, PubMed, SEC EDGAR 등 공식 공개 데이터를 일반 참고용으로 집계하며, 의학적 조언, 진단, 치료 권고 또는 투자 조언이 아닙니다.

임상시험

A Clinical and Imaging Registry of Transcatheter Aortic Valve Implantation Using JenaValve System/ J-Valve System for Patients With Pure Aortic Regurgitation

NCT: NCT07021612 · RECRUITING

NCT IDNCT07021612
상태RECRUITING
시작일2025-04-01
완료2028-09-30
SponsorPrince of Wales Hospital, Shatin, Hong Kong (OTHER)
First posted
Last updated

간략 요약

Aortic regurgitation (AR) is not uncommon. Transcatheter aortic valve implantation (TAVI) for treating pure aortic regurgitation is a potential future treatment option for pure AR especially in patients having high risk for open heart surgery. TAVI using dedicated device for pure AR has a different anchor mechanism to TAVI for aortic stenosis (AS). AR patientsalso have different cardiac flow pattern, aortic root pathology and left ventricular remodeling pattern compared to AS patients. Subclinical leaflet thrombosis has been described in AS patient receiving TAVI, which will affect the durability and antithrombotic regime. Follow-up imaging for dedicated TAVI device in AR patient is limited.

공식 출처

ClinicalTrials.gov에서 보기 →

데이터는 ClinicalTrials.gov API에서 제공됩니다. 최신 상태는 공식 기록을 확인하세요.

↑